ES2127531T3 - Medicamento para la inmunosupresion prolongada y la eliminacion de celulas tumorales. - Google Patents

Medicamento para la inmunosupresion prolongada y la eliminacion de celulas tumorales.

Info

Publication number
ES2127531T3
ES2127531T3 ES95920061T ES95920061T ES2127531T3 ES 2127531 T3 ES2127531 T3 ES 2127531T3 ES 95920061 T ES95920061 T ES 95920061T ES 95920061 T ES95920061 T ES 95920061T ES 2127531 T3 ES2127531 T3 ES 2127531T3
Authority
ES
Spain
Prior art keywords
group
antibody
medication
elimination
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95920061T
Other languages
English (en)
Inventor
Stefan Thierfelder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Original Assignee
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH filed Critical Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt GmbH
Application granted granted Critical
Publication of ES2127531T3 publication Critical patent/ES2127531T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Abstract

LA INVENCION SE REFIERE A ANTICUERPOS FRENTE A CELULAS T COMO AGENTES TERAPEUTICOS. EL OBJETIVO DE LA INVENCION ES DISPONER DE ANTICUERPOS PARA EL TRATAMIENTO CLINICO DE PROLONGACION DEL EFECTO INMUNOSUPRESOR DE ANTICUERPOS, EVITANDO LA FORMACION DE ANTI-ANTICUERPOS. ESTO SE CONSIGUE MEDIANTE ANTICUERPOS QUE CONSTAN DE COMO MINIMO DE DOS GRUPOS DISTINTOS, QUE SE ADMINISTRAN POR SEPARADO EN MOMENTOS DISTINTOS Y EN LOS QUE SE DISTINGUEN COMO MINIMO UN ANTICUERPO DEL GRUPO B EN LAS PARTES CONSTANTES DE LAS CADENAS PESADAS DE UN ANTICUERPO DEL GRUPO A Y DE FORMA QUE EL GRUPO A, QUE SE APLICA EN PRIMER LUGAR UNA O VARIAS VECES, ACTUA ELIMINANDO LAS CELULAS T, MIENTRAS QUE EL GRUPO B (QUE SE APLICA DESPUES DE UN PERIODO DE TIEMPO) ACTUA ELIMINANDO LAS CELULAS T Y/O MODULANDO EL ANTIGENO DE LAS CELULAS T.
ES95920061T 1994-06-18 1995-05-19 Medicamento para la inmunosupresion prolongada y la eliminacion de celulas tumorales. Expired - Lifetime ES2127531T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4421391A DE4421391C1 (de) 1994-06-18 1994-06-18 Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression

Publications (1)

Publication Number Publication Date
ES2127531T3 true ES2127531T3 (es) 1999-04-16

Family

ID=6520949

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95920061T Expired - Lifetime ES2127531T3 (es) 1994-06-18 1995-05-19 Medicamento para la inmunosupresion prolongada y la eliminacion de celulas tumorales.

Country Status (10)

Country Link
US (3) US5830473A (es)
EP (1) EP0802924B1 (es)
JP (1) JPH10505325A (es)
AT (1) ATE175215T1 (es)
CA (1) CA2193092A1 (es)
DE (2) DE4421391C1 (es)
DK (1) DK0802924T3 (es)
ES (1) ES2127531T3 (es)
GR (1) GR3029483T3 (es)
WO (1) WO1995035321A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
WO1999051247A1 (en) * 1998-04-03 1999-10-14 Osiris Therapeutics, Inc. Use of human mesenchymal stem cells to induce t-cell apoptosis
DE19953517C1 (de) * 1999-11-05 2001-08-09 Medac Klinische Spezialpraep Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20050084967A1 (en) * 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
EP1539929B1 (en) * 2002-06-28 2013-04-10 Life Technologies Corporation Methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
CA2646329C (en) 2006-03-20 2018-07-03 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
EP2197491A4 (en) 2007-09-04 2011-01-12 Univ California HIGHAFFINE ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES TO CANCER AND TO THE DETECTION OF CANCER
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
EP2398504B1 (en) 2009-02-17 2018-11-28 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
EP3511023A1 (en) 2009-12-02 2019-07-17 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
CN115960230A (zh) 2015-08-07 2023-04-14 伊麦吉纳博公司 靶向分子的抗原结合构建体
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa

Also Published As

Publication number Publication date
DE59504707D1 (de) 1999-02-11
ATE175215T1 (de) 1999-01-15
DE4421391C1 (de) 1995-11-30
US20050069543A1 (en) 2005-03-31
WO1995035321A1 (de) 1995-12-28
EP0802924B1 (de) 1998-12-30
US5830473A (en) 1998-11-03
US6290955B1 (en) 2001-09-18
CA2193092A1 (en) 1995-12-28
JPH10505325A (ja) 1998-05-26
EP0802924A1 (de) 1997-10-29
GR3029483T3 (en) 1999-05-28
DK0802924T3 (da) 1999-08-30

Similar Documents

Publication Publication Date Title
ES2127531T3 (es) Medicamento para la inmunosupresion prolongada y la eliminacion de celulas tumorales.
ATE161582T1 (de) Monoklonale antikörper der maus
PT724456E (pt) Anticorpos contra cd4
BR9914116A (pt) Composições e métodos para imunoterapia especìfica de wt1
DE69429095D1 (de) Humanisierte antikoerper
DE69435126D1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
DE69939820D1 (de) Internalisierende erbb2 antikörper
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
AU7690596A (en) Anti-CD6 monoclonal antibodies and their uses
UA50708C2 (uk) Моноклональне антитіло, яке має здатність розпізнавати антиген, який викликає апоптоз мієлоїдних клітин, фрагмент f(ab)2 моноклонального антитіла, гібридома ferm bp-4382
CA2212150A1 (en) Monoclonal antibodies for human osteogenic cell surface antigens
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
SE8700467D0 (sv) Cross-protective human monoclonal antibody compositions
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
BR0116686A (pt) Anticorpos anti-cd28 silenciados e uso dos mesmos
DE3585049D1 (de) Monoklonale antikoerper.
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
ATE209041T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendung
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
SU572590A1 (ru) Струйный усилитель
RU1826866C (ru) Ретрактор
ES2051870T3 (es) Anticuerpo monoclonal capaz de suprimir la proliferacion de linfocitos t.
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
TH11152EX (th) สารปลดปล่อย

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 802924

Country of ref document: ES